Inactive Instrument

News Shilpa Medicare Ltd NSE India S.E.

Equities

INE790G01023

End-of-day quote NSE India S.E. Other stock markets
- ^INR	-

24/05	Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024
23/05	Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024	24/05
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	23/05	CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	14/05	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	18/04	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	17/04	MT
Shilpa Medicare Gets Board Nod to Launch QIP	09/04	MT
Shilpa Medicare's Life Science Arm Names CEO	28/03	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	01/03	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	26/02	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	12/02
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	19/01	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	03/11	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	11/23/11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	04/23/04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	04/23/04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	01/23/01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	25/23/25	MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023	11/23/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shilpa Medicare Ltd NSE India S.E.

Equities

INE790G01023

Summary

Filters